Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
304 studies found for:    nash
Show Display Options
Rank Status Study
21 Recruiting Comparing Effects of Liraglutide and Bariatric Surgery on Weight Loss, Liver Function, Body Composition, Insulin Resistance, Endothelial Function and Biomarkers of Non-alcoholic Steatohepatitis (NASH) in Obese Asian Adults
Conditions: Non-alcoholic Fatty Liver Disease (NAFLD);   Weight Loss;   Non-alcoholic Steatohepatitis (NASH)
Interventions: Behavioral: Lifestyle modification;   Drug: Liraglutide
22 Active, not recruiting Safety and Efficacy of Simtuzumab (GS-6624) in Adults With Advanced Liver Fibrosis But Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)
Condition: Non-Alcoholic Steatohepatitis (NASH)
Interventions: Biological: Simtuzumab;   Biological: Placebo
23 Completed Clearance of NRL972 in Patients With Cirrhosis, Nonalcoholic Steatohepatitis (NASH) and in Healthy Volunteers
Conditions: Hepatic Cirrhosis;   Nonalcoholic Steatohepatitis
Intervention: Drug: NRL972
24 Completed Exploratory Study to Assess the Short Term Effect on Liver Enzymes and the Safety of TRO19622 in Patients With Non-Alcoholic Steatohepatitis (NASH)
Condition: Non-Alcoholic Steatohepatitis (NASH)
Intervention: Drug: TRO19622
25 Active, not recruiting Clinical Trial to Evaluate Efficacy of GR-MD-02 for Treatment of Liver Fibrosis in Patients With NASH With Advanced Fibrosis
Condition: Nonalcoholic Steatohepatitis
Interventions: Drug: GR-MD-02;   Drug: Placebo
26 Completed Omega 3 Fish Oil Supplements vs. Placebo for Patients With Non-alcoholic Steatohepatitis (NASH)
Conditions: Non-alcoholic Steatohepatitis;   Fatty Liver
Interventions: Drug: Omega 3 Fish Oil supplements;   Drug: Placebo
27 Recruiting Open-Label Study To Evaluate Efficacy, Safety, Tolerability & PK of MN-001 on HDL & Triglyceride in NASH & NAFLD Subjects
Conditions: Non-alcoholic Steatohepatitis;   Hypertriglyceridemia;   Non-alcoholic Fatty Liver Disease
Intervention: Drug: MN-001
28 Recruiting Prospective Cohort Assessing the Role of the Genotoxin Colibactin From Escherichia Coli B2 in the Genesis of NASH
Condition: Non-alcoholic Fatty Liver Disease
Interventions: Biological: liver biopsy;   Biological: collection of stools;   Biological: blood sample
29 Active, not recruiting Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
Condition: Hypertension, Portal
Interventions: Drug: GR-MD-02;   Drug: Placebo
30 Completed Effect of Metformin on Disease Progression in Patients With Cryptogenic Cirrhosis (NASH-related Cirrhosis) With Diabetes or Impaired Glucose Tolerance or Insulin Resistance
Condition: NASH Related Cirrhosis
Interventions: Drug: Metformin;   Drug: Insulin
31 Completed
Has Results
Pentoxifylline/Nonalcoholic Steatohepatitis (NASH) Study: The Effect of Pentoxifylline on NASH
Conditions: Nonalcoholic Steatohepatitis;   Liver Diseases
Interventions: Drug: Pentoxifylline;   Drug: Placebo
32 Recruiting Safety, Tolerability and Efficacy Study of 12 Weeks LJN452 Treatment in NASH Patients
Condition: Non-alcoholic Steatohepatitis
Interventions: Drug: LJN452;   Drug: Placebo
33 Recruiting Volixibat (SHP626) in the Treatment of Adults With Nonalcoholic Steatohepatitis (NASH)
Condition: Non-Alcoholic Steatohepatitis
Interventions: Drug: SHP626;   Drug: Placebo
34 Completed The Role of Leptin Receptors in NASH
Conditions: Nonalcoholic Steatohepatitis;   Metabolic Syndrome
Intervention: Other: no interventions, only regular blood-draw
35 Recruiting Trial Comparing Metformin Versus Placebo in Non Alcoholic Steatohepatitis (NASH) Patients Receiving Bariatric Surgery for Obesity
Condition: Obesity
Intervention: Drug: Metformin
36 Not yet recruiting EUS Guided Core Liver Biopsy and IGB Placement for the Diagnosis and Management of NASH and Obesity
Conditions: Obesity;   Non-Alcoholic Steatohepatitis
Interventions: Device: ORBERA Intragastric Balloon;   Procedure: Endoscopic Ultrasound Guided Core Liver Biopsy
37 Recruiting A Clinical Trial to Evaluate the Efficacy and Safety of Two Aramchol Doses Versus Placebo in Patients With NASH
Condition: Fatty Liver
Intervention: Drug: Aramchol
38 Completed Omega 3 Supplementation in Fatty Liver
Condition: Fatty Liver
Intervention: Dietary Supplement: Omega 3
39 Active, not recruiting Efficacy and Safety Study of Cenicriviroc for the Treatment of NASH in Adult Subjects With Liver Fibrosis
Condition: Nonalcoholic Steatohepatitis
Interventions: Drug: Cenicriviroc;   Drug: Placebo
40 Terminated Effects of Rosiglitazone and Alpha-lipoic Acid on the Patients With Pathologically Proved NASH
Condition: NASH (Non-alcoholic Steato-hepatitis)
Interventions: Drug: Rosiglitazone;   Drug: alpha-lipoic acid;   Drug: Rosiglitazone/alpha-lipoic acid

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years